Live Breaking News & Updates on Professor Rick Tarleton

Stay updated with breaking news from Professor rick tarleton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease

On track to announce Phase 2 clinical data. ....

South Korea , Rick Tarleton , Eric Easom , Anacor Pharmaceuticals Inc , Therapeutics Inc , Melinda Gates Foundation , Development Rd Expenses , University Of Georgia , University Of Georgia Research Foundation , Chief Executive , Georgia Research Foundation , Recent Business Updates , Pivotal Phase , New Epetraborole Data , Infectious Disease Society , Develop Boron Containing Product Candidates , Anacor Pharmaceuticals , Professor Rick Tarleton , Melinda Gates , Private Securities Litigation Reform Act ,

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease - AN2 Therapeutics (NASDAQ:ANTX)

License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in ....

United States , Eric Easom , Rick Tarleton , Therapeutics Inc , Department Of Cellular Biology , Anacor Pharmaceuticals Inc , University Of Georgia Research Foundation , University Of Georgia , University Of Georgia Chagas , World Health Organization , Georgia Chagas , Georgia Research Foundation , Anacor Pharmaceuticals , Professor Rick Tarleton , Chief Executive Officer , Regents Professor , Emerging Global Diseases , Cellular Biology , Neglected Tropical Disease , Latin America , Private Securities Litigation Reform Act ,

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

License enables advancement of AN2-502998 , a boron-based small molecule therapeutic under development for the treatment of Chagas disease

IND-enabling preclinical studies well underway in. ....

United States , Eric Easom , Rick Tarleton , University Of Georgia , World Health Organization , Therapeutics Inc , University Of Georgia Research Foundation , Department Of Cellular Biology , Anacor Pharmaceuticals Inc , Georgia Research Foundation , Anacor Pharmaceuticals , Professor Rick Tarleton , Chief Executive Officer , Regents Professor , Emerging Global Diseases , Cellular Biology , Neglected Tropical Disease , Latin America , Private Securities Litigation Reform Act ,